

Resource Summary Report

Generated by [RRID](#) on Sep 3, 2026

IGFBP-3, Intact Antibody Pair Kit

RRID:AB_2783688

Type: Antibody

Proper Citation

Ansh Labs Cat# AL-149, RRID:AB_2783688

Antibody Information

URL: http://antibodyregistry.org/AB_2783688

Proper Citation: Ansh Labs Cat# AL-149, RRID:AB_2783688

Target Antigen: IGFBP-3

Clonality: monoclonal

Comments: Applications: ELISA

Antibody Name: IGFBP-3, Intact Antibody Pair Kit

Description: This monoclonal targets IGFBP-3

Target Organism: Human, Bovine, Caprine, Rabbit, Mouse

Antibody ID: AB_2783688

Vendor: Ansh Labs

Catalog Number: AL-149

Record Creation Time: 20231110T032957+0000

Record Last Update: 20260829T211130+0000

Ratings and Alerts

No rating or validation information has been found for IGFBP-3, Intact Antibody Pair Kit.

No alerts have been found for IGFBP-3, Intact Antibody Pair Kit.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Barrios V, et al. (2024) Reduction in Pappalysin-2 Levels and Lower IGF-I Bioavailability in Female Adolescents With Anorexia Nervosa. The Journal of clinical endocrinology and metabolism, 109(3), e920.

Güemes M, et al. (2024) Implication of Pappalysins and Stanniocalcins in the Bioavailability of IGF-I in Children With Type 1 Diabetes Mellitus. Journal of the Endocrine Society, 8(6), bvae081.

Martín-Rivada Á, et al. (2024) Prepubertal children with obesity have high free IGF-1 levels and accelerated growth despite reduced pappalysin levels. The Journal of clinical endocrinology and metabolism.

Barrios V, et al. (2023) Increased IGFBP proteolysis, IGF-I bioavailability and pappalysin levels in children with Prader-Willi syndrome. The Journal of clinical endocrinology and metabolism.